Senn Chemicals
Private Company
Funding information not available
Overview
Senn Chemicals is a long-established, privately-owned Swiss CDMO with deep expertise in peptide and amino acid derivative synthesis. The company leverages both solid-phase and solution-phase synthesis technologies, with capabilities to handle complex peptides over 40 amino acids and large-scale production up to 2,500 liters. Recently acquired by Granules India, Senn is positioned to expand its capacity and serve the rapidly growing global peptide therapeutics market as a reliable, high-quality manufacturing partner.
Technology Platform
Dual expertise in solution-phase (up to 2,500L) and solid-phase peptide synthesis (SPPS) for complex peptides >40 amino acids, with capabilities in Fmoc/Boc/Z chemistry, preparative HPLC, lyophilization, and development toward HPAPI manufacturing.
Opportunities
Risk Factors
Competitive Landscape
Senn competes in the niche but growing peptide CDMO space against larger players like Bachem, PolyPeptide, and CordenPharma, as well as numerous smaller specialized firms. Its key differentiators are its long-standing Swiss heritage, focus on complex synthesis, and a partnership-oriented model. The acquisition now pits it against the scaled resources of its larger competitors.